AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$PCVX

Wassil Jim sold $128K of PCVX

Wassil Jim (EVP, Chief Scientific Ofc, COO) sold 2,250 shares of Vaxcyte, Inc. (PCVX) at an average of $56.67 ($56.65–$57.09, $0.13M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wassil Jim
Published Oct 2, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PCVX
Neutral
medium confidence
Mentioned
$PCVX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PCVXNeutralLow
01

Why it matters

The sale is modest and unlikely to move the stock significantly, but it provides transparency on insider holdings.

02

Market read

Primary disclosure of a small insider sale; limited trading relevance.

03

What to watch

Potential upcoming FDA decisions or trial results could amplify the impact of this sale.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses an insider's 10b5‑1 sale of Vaxcyte shares.

Company-level read

Ticker impact

$PCVXNeutralMedium confidence
Context

Officer Wassil Jim sold 2,250 shares of Vaxcyte for $127.5K via a 10b5‑1 plan, reducing his stake to 145,435 shares.

Expected impact

likely slight downward pressure as the market prices the insider divestment

Evidence & confidence

Insider sales of this size are routine and typically have limited impact, but the disclosed 10b5‑1 plan signals a planned reduction in holdings.

Market effects

Sector

Minimal effect on the biotech sector; no broader industry catalyst.

Regional

Negligible impact on US markets.

Global

None

Counterpoint

What could challenge this read

If the insider sale reflects concerns about upcoming data, the stock could face more downside.

Key entities

  • company
    Vaxcyte, Inc.

    Biotech firm developing DNA‑based vaccines and therapeutics.

  • person
    Wassil Jim

    Executive Vice President, Chief Scientific Officer and COO of Vaxcyte.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PCVX insider trading history →

Related articles

OCT 9
$PCVXHighAI 9/10

Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes

Vaxcyte (PCVX) closed public offerings raising $1.15B, including 8.58M shares at $64 each, pre-funded warrants, and $575M in convertible notes. Proceeds will fund clinical trials, manufacturing, and R&D. Joint bookrunners included Jefferies, Leerink, and BofA.

marketscreener.com2 min
OCT 9
$MRNAHighAI 8/10

A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally - Moderna (NASDAQ:MRNA), BioNTec

A new NIH initiative to accelerate personalized cancer vaccine development has sparked a rally in biotech stocks. Moderna, Novavax, BioNTech, Pfizer, Merck, and Vaxcyte saw gains. The program, launching in December, focuses on pancreatic, liver, colorectal cancers, and childhood tumors. Moderna and Merck reported positive Phase 3 results for their mRNA cancer vaccine in August. BioNTech is advancing multiple cancer therapies.

benzinga.com2 min